Markets:

Overview

News

Currencies

International

Treasuries

Novartis AG Common Stock (NY:NVS)

150.86 +2.25 (+1.51%)

Streaming Delayed Price Updated: 3:30 PM EDT, Mar 25, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

56 57 Next >

The $6.7 Billion Pivot: A Deep Dive into Terns Pharmaceuticals (TERN) and the Merck Acquisition

Today 10:41 EDT

On this Wednesday, March 25, 2026, the biotechnology sector has been electrified by the announcement that Merck & Co. (NYSE: MRK) will acquire Terns Pharmaceuticals, Inc. (NASDAQ: TERN) in an all-cash...

Via Finterra

Retirees: Collect a High Dividend While Diversifying Your Portfolio With This ETF ↗

March 24, 2026

The Vanguard International High Dividend Yield ETF holds more than 1,500 stocks and yields 3.3%.

Via The Motley Fool

Topics ETFs Retirement

3 ETFs Built for the Volatile Market We're Seeing in March 2026 ↗

March 22, 2026

These ETFs can handle volatile markets.

Via The Motley Fool

Topics ETFs Economy Stocks

Novartis AG-Sponsored ADR (NYSE:NVS): A Methodical Pick for Steady Dividend Income ↗

March 13, 2026

Via Chartmill

Novartis AG-Sponsored ADR (NYSE:NVS): A Quality Dividend Stock with Strong Fundamentals ↗

February 19, 2026

Via Chartmill

Novartis Strikes $3 Billion Deal For Next-Gen Breast Cancer Drug ↗

March 20, 2026

Novartis to acquire SNV4818 for $3 billion, targeting PIK3CA-mutated breast cancer with a potentially safer, precision-based approach.

Via Benzinga

The High-Stakes Gambit: How Healthcare Giants are 'Front-Loading' Megadeals to Outrun Regulatory Storms

March 18, 2026

In the face of the most aggressive antitrust environment in decades and the sweeping legislative changes of the 2025 "One Big Beautiful Bill Act" (OBBBA), the healthcare sector has not retreated from...

Via MarketMinute

Topics Artificial Intelligence Intellectual Property

Novartis Advances Dermatology Portfolio With Cosentyx FDA Approval For Pediatric Patients ↗

March 16, 2026

FDA approves Novartis' Cosentyx for moderate to severe hidradenitis suppurativa in patients aged 12 and older, expanding treatment options.

Via Benzinga

VYMI: This International ETF Could Help You Earn Higher Dividends ↗

March 12, 2026

If you want international stock exposure with a chance for higher dividend yields, this Vanguard ETF could be a good buy.

Via The Motley Fool

Topics ETFs

3 ETFs to Avoid as Oil Shock Hits Markets ↗

March 12, 2026

Via MarketBeat

Topics ETFs

Vertex Pharmaceuticals Surges as Breakthrough Kidney Data Sets New Gold Standard for IgA Nephropathy

March 10, 2026

Shares of Vertex Pharmaceuticals (Nasdaq: VRTX) climbed more than 8% today, reaching a record high as the biotechnology giant unveiled spectacular interim results from its pivotal Phase 3 RAINIER...

Via MarketMinute

Pfizer (PFE) 2026 Research Feature: The High-Stakes Pivot to Oncology and Obesity

March 10, 2026

As of today, March 10, 2026, Pfizer Inc. (NYSE: PFE) stands at a pivotal crossroads in its 177-year history. After experiencing a meteoric rise during the COVID-19 pandemic followed by a sobering...

Via Finterra

Topics Economy Intellectual Property Lawsuit

Forget Amarin: This Oft-Overlooked Pharma Powerhouse Is a Better Buy Now ↗

March 03, 2026

One is speculative, the other is a reliable blue chip company.

Via The Motley Fool

Topics Intellectual Property

As Investors Flee U.S. Equities, This Global ETF Is Outperforming ↗

March 02, 2026

Via MarketBeat

Topics ETFs

Second HeLa Lawsuit Resolved As Novartis Reaches Confidential Settlement ↗

February 28, 2026

Novartis reached a confidential settlement with Henrietta Lacks' family, resolving a second lawsuit over the nonconsensual use of HeLa cells.

Via Benzinga

Topics Lawsuit

Pfizer Secures Full FDA Approval for BRAFTOVI in First-Line Colorectal Cancer, Bolstering Oncology Growth Strategy

February 26, 2026

In a move that solidifies a new standard of care for a high-risk patient population, the U.S. Food and Drug Administration (FDA) has granted full approval to Pfizer Inc. (NYSE: PFE) for its BRAFTOVI...

Via MarketMinute

Topics Economy Intellectual Property

Stock Market Today, Feb. 25: Novo Nordisk Dips After Announcing $2.1 Billion Partnership With Vivtex for Oral Drug-Delivery Technologies ↗

February 25, 2026

Investors weigh steep GLP‑1 price cuts against a multibillion‑dollar oral obesity push, fresh analyst caution, and a new partnership, today, Feb. 25, 2026.

Via The Motley Fool

Topics Stocks

Eli Lilly Bolsters Genetic Medicine Portfolio with $2.4 Billion Acquisition of Orna Therapeutics

February 25, 2026

In a definitive move to dominate the next frontier of immunology and oncology, Eli Lilly and Company (NYSE: LLY) announced on February 9, 2026, its acquisition of Orna Therapeutics for a total...

Via MarketMinute

Topics Intellectual Property

Could Novartis Stock Quietly Help You Build a Millionaire Retirement Portfolio? ↗

February 24, 2026

It has the qualities of a buy-and-forget stock.

Via The Motley Fool

Topics Intellectual Property Retirement

Arvinas (ARVN) Q4 2025 Earnings Call Transcript ↗

February 24, 2026

Arvinas (ARVN) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Stock Market Today, Feb. 23: Novo Nordisk Plunges 16% After Obesity Drug Falls Short ↗

February 23, 2026

Today, Feb. 23, 2026, a pivotal obesity‑drug trial setback forces investors to rethink Novo Nordisk’s strategy.

Via The Motley Fool

Topics Stocks

Novartis: This Big Pharma Giant Could Be a Sleep‑at‑Night Core Holding for Decades ↗

February 22, 2026

Novartis has a solid portfolio of drugs and a pipeline that should keep the business humming.

Via The Motley Fool

Topics Intellectual Property

Pfizer’s BRAFTOVI BREAKWATER Trial Delivers Landmark Survival Gains in Colorectal Cancer

February 19, 2026

NEW YORK — Pfizer Inc. (NYSE: PFE) has announced breakthrough results from its Phase 3 BREAKWATER clinical trial, demonstrating that its BRAFTOVI (encorafenib) regimen significantly improves both...

Via MarketMinute

A Look Into Novartis Inc's Price Over Earnings ↗

February 17, 2026

Via Benzinga

Promethos Capital Liquidates $4 Million Sprouts Farmers Market Position: Should Investors Sell, Too? ↗

February 16, 2026

Sprouts Farmers Market runs a national grocery chain focused on fresh, natural, and organic foods for health-conscious shoppers.

Via The Motley Fool

Topics Regulatory Compliance

Buy 2 Vanguard Index Funds to Beat the S&P 500 in the Next Decade, According to Wall Street Analysts ↗

February 16, 2026

Goldman Sachs expects European and emerging-market equities to beat the U.S. stock market over the next decade.

Via The Motley Fool

Topics ETFs Stocks

Novartis Says Conditionally Approved Kidney Drug Shows Long-Term Promise ↗

February 13, 2026

Novartis shared final Phase 3 results showing Vanrafia may slow kidney function decline in adults with IgA nephropathy.

Via Benzinga

Alnylam Pharmaceuticals (ALNY): The RNAi Pioneer’s 2026 Breakout and the Battle for Cardiovascular Dominance

February 12, 2026

As of February 12, 2026, Alnylam Pharmaceuticals (NASDAQ: ALNY) has officially transcended its status as a high-potential biotech and entered the pantheon of global pharmaceutical powerhouses. Known as...

Via Finterra

Topics Economy Intellectual Property

Incyte (INCY) Deep Dive: Navigating the 2026 Crossroads Following Earnings Miss

February 11, 2026

As of February 11, 2026, Incyte Corporation (NASDAQ: INCY) finds itself at a pivotal crossroads. Known for over a decade as a one-drug powerhouse centered on the hematology blockbuster Jakafi, the...

Via Finterra

Topics Economy Intellectual Property

Biogen (BIIB) Q4 Earnings Preview: The "New Biogen" Emerges as Alzheimer's and Rare Disease Pipelines Take Center Stage

February 06, 2026

Biogen Inc. (NASDAQ: BIIB) reported its fourth-quarter and full-year 2025 financial results on February 6, 2026, signaling a definitive shift from a legacy company plagued by patent cliffs to a leaner,...

Via MarketMinute

Topics Intellectual Property

< Previous 1 2 3 4 5 6 7 8 9

...

56 57 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.